<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Experimental and Clinical Surgery</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Experimental and Clinical Surgery</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник экспериментальной и клинической хирургии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2070-478X</issn><issn publication-format="electronic">2409-143X</issn><publisher><publisher-name xml:lang="en">Voronezh State Medical University named after N.N. Burdenko</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1283</article-id><article-id pub-id-type="doi">10.18499/2070-478X-2020-13-1-61-69</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Review of literature</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзор литературы</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">RADIOEMBOLIZATION AS A METHOD FOR THE TREATMENT OF UNRESECTABLE PRIMARY AND METASTATIC LIVER CANCER (LITERATURE REVIEW)</article-title><trans-title-group xml:lang="ru"><trans-title>Радиоэмболизация как метод лечения нерезектабельного первичного и метастатического рака печени.</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1551-3127</contrib-id><contrib-id contrib-id-type="spin">4770-5722</contrib-id><name-alternatives><name xml:lang="en"><surname>Lebedev</surname><given-names>Dmitry Petrovich</given-names></name><name xml:lang="ru"><surname>Лебедев</surname><given-names>Дмитрий Петрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, interventional radiologist</p></bio><bio xml:lang="ru"><p>Врач по рентгенэндоваскулярным диагностике и лечению</p></bio><email>lebedevdp@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8539-4392</contrib-id><contrib-id contrib-id-type="scopus">41262312000</contrib-id><contrib-id contrib-id-type="researcherid">V-7148-2017</contrib-id><contrib-id contrib-id-type="spin">4316-4651</contrib-id><name-alternatives><name xml:lang="en"><surname>Panchenkov</surname><given-names>Dmitry Nikolaevich</given-names></name><name xml:lang="ru"><surname>Панченков</surname><given-names>Дмитрий Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor of Surgery, Head of the Laboratory of Minimally Invasive Surgery</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, заведующий лабораторией минимально инвазивной хирургии НИМСИ</p></bio><email>dnpanchenkov@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6209-4194</contrib-id><contrib-id contrib-id-type="scopus">36152653200</contrib-id><contrib-id contrib-id-type="spin">3240-4335</contrib-id><name-alternatives><name xml:lang="en"><surname>Ivanov</surname><given-names>Yuri Viktorovich</given-names></name><name xml:lang="ru"><surname>Иванов</surname><given-names>Юрий Викторович</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, PhD, Professor of Surgery, Head of the Department of Surgery, Honored Doctor of the Russian Federation</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зав. отделением хирургии; ведущий научный сотрудник, Заслуженный врач РФ</p></bio><email>ivanovkb83@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8776-944X</contrib-id><contrib-id contrib-id-type="scopus">55233828400</contrib-id><contrib-id contrib-id-type="spin">6203-5870</contrib-id><name-alternatives><name xml:lang="en"><surname>Astakhov</surname><given-names>Dmitry Anatolievich</given-names></name><name xml:lang="ru"><surname>Астахов</surname><given-names>Дмитрий Анатольевич</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, Leading Researcher of Laboratory of Minimally Invasive Surgery; Oncologist, Oncology Department</p></bio><bio xml:lang="ru"><p>к.м.н., ведущий научный сотрудник лаборатории минимально инвазивной хирургии НИМСИ; врач онколог отделения онкологии</p></bio><email>astakhovd@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0277-9455</contrib-id><contrib-id contrib-id-type="spin">8428-4518</contrib-id><name-alternatives><name xml:lang="en"><surname>Zvezdkina</surname><given-names>Elena Alexandrovna</given-names></name><name xml:lang="ru"><surname>Звездкина</surname><given-names>Елена Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD., department of roentgenology with MRI group</p></bio><bio xml:lang="ru"><p>к.м.н., врач отделения рентгенологии с кабинетами МРТ</p></bio><email>zvezdkina@yandex.ru</email><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Federal scientific and clinical center of specialized types of medical care and medical technologies FMBA of Russia</institution></aff><aff><institution xml:lang="ru">Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Moscow state medical and dental University A.I. Evdokimov Ministry of health Russian Federation</institution></aff><aff><institution xml:lang="ru">Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Moscow state medical and dental University A.I. Evdokimov Ministry of health Russian Federation.</institution></aff><aff><institution xml:lang="ru">Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Central Research Institute of Tuberculosis Ministry of Science and Higher Education of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Центральный научно-исследовательский институт туберкулеза" Министерства науки и высшего образования Российской федерации</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Federal scientific and clinical center of specialized types of medical care and medical technologies FMBA of Russia.</institution></aff><aff><institution xml:lang="ru">Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России.</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-02-25" publication-format="electronic"><day>25</day><month>02</month><year>2020</year></pub-date><volume>13</volume><issue>1</issue><issue-title xml:lang="ru"/><fpage>61</fpage><lpage>69</lpage><history><date date-type="received" iso-8601-date="2019-02-03"><day>03</day><month>02</month><year>2019</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Voronezh N.N. Burdenko State Medical University</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Voronezh N.N. Burdenko State Medical University</copyright-holder><copyright-holder xml:lang="ru">ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnik-surgery.com/journal/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnik-surgery.com/journal/article/view/1283">https://vestnik-surgery.com/journal/article/view/1283</self-uri><abstract xml:lang="en"><p>A review of the literature on one of the methods of treatment of unresectable primary and metastatic liver cancer, namely radio embolization, is presented. A detailed description of the procedure for performing radioembolization of the liver vessels, possible complications, indications and contraindications to this method, lists the necessary equipment and tools. Particular attention is paid to the description of the microspheres used in radioembolization. A modern review of clinical studies, including those still unfinished, devoted to the method of radioembolization with unresectable primary and metastatic liver cancer is given.</p></abstract><trans-abstract xml:lang="ru"><p>Представлен обзор литературы по одному из методов лечения нерезектабельного первичного и метастатического рака печени, а именно - радиоэмболизации. Подробно описана методика выполнения радиоэмболизации сосудов печени, возможные осложнения, показания и противопоказания к данному методу, перечислено необходимое оборудование и инструментарий. Особое внимание уделено описанию используемых при радиоэмболизации микросфер. Приведен современный обзор клинических исследований, в том числе еще незаконченных, посвященных методу радиоэмболизации при нерезектабельном первичном и метастатическом раке печени.</p></trans-abstract><kwd-group xml:lang="en"><kwd>liver</kwd><kwd>hepatocellular carcinoma</kwd><kwd>metastatic carcinoma</kwd><kwd>method of radioembolization of the liver</kwd><kwd>clinical trial.</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>печень, гепатоцеллюлярный рак, метастатический рак, метод радиоэмболизации сосудов печени, клиническое исследование</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. World Cancer Report 2014 / edited by Bernard W. Stewart and Christopher P. Wild //. Published by the International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France. 2014. p. 17-19.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma / edited by Peter R. Galle, Alejandro Forner, Josep M. Llovet et al. //. J. Hepatol. 2018. p. 195-197.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Andrews, J. C. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up / James C. Andrews, Suzette C. Walker, Robert J. Ackermann et al. //. J Nucl Med. 1994; October. V. 35 (10). p. 1637-1644.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Cao X. Hepatic radioembolization with Yttrium-90 glass microspheres for treatment of primary liver cancer / X. Cao, N. He, J. Sun et al. //. Chin Med J (Engl). 1999; May. V. 112 (5). p. 430-432.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Herba, M. J. Radioembolization for hepatic metastases / Milton J. Herba, Michael P. Thirlwell //. Semin Oncol. 2002; Apr. V. 29 (2). p. 152-159.</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Dolgushin, B.I. Locoregional interventional radiological technologies in the treatment of hepatocellular cancer / B.I. Dolgushin, E.R. Virshke, V.Yu. Kosyrev et al. //. Farmateka. 2012. No. S1. C. 30-37.</mixed-citation><mixed-citation xml:lang="ru">6. Долгушин, Б. И. Локорегиональные интервенционнорадиологические технологии в лечении гепатоцеллюлярного рака / Б. И. Долгушин, Э. Р. Виршке, В. Ю. Косырев с соавт. //. Фарматека. 2012. № S1. C. 30-37.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Tarazov, P. G. Arterial radioembolization of liver malignancies with yttrium-90 glass microspheres: first experience / P. G. Tarazov, A. A. Polikarpov, A. A. Ivanova //. Diagnostic and interventional radiology. 2014. t. 8. № 4. C. 59-66.</mixed-citation><mixed-citation xml:lang="ru">7. Таразов, П. Г. Arterial radioembolization of liver malignancies with yttrium-90 glass microspheres: first experience / П. Г. Таразов, А. А. Поликарпов, А. А. Иванова //. Диагностическая и интервенционная радиология. 2014. т. 8. № 4. C. 59-66.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Lyadov, V. K. Therapy of inoperable hepatocellular cancer by selective transarterial radioembolization with yttrium-90 microspheres / K. V. Lyadov, A. D. Kaprin, A. G. Rerberg et al. //. Oncology. 2018. t. 7. № 3. C. 55-60.</mixed-citation><mixed-citation xml:lang="ru">8. Лядов, В. К. Терапия неоперабельного гепатоцеллюлярного рака селективной трансартериальной радиоэмболизацией микросферами иттрия-90 / К. В. Лядов, А. Д. Каприн, А. Г. Рерберг с соавт. //. Онкология. 2018. т. 7. № 3. C. 55-60.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><mixed-citation>9. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma / edited by Josep M. Llovet (EASL), Michel Ducreux (EORTC) //. J Hepatol. 2012; Apr. V. 56 (4). p. 908-943.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Chauhan, N. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial / N. Chauhan, J. Bukovcan, E. Boucher et al //. JMIR Res Protoc. 2018; Aug. V. 7 (8). e 11234.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Vilgrain, V. Radioembolisation with yttrium‐90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial / Valérie Vilgrain, Mohamed Abdel-Rehim, Annie Sibert et al. //. Trials. 2014. 15:474.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Vilgrain, V. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH) / Valérie Vilgrain, Helena Pereira, Eric Assenat et al. //. Lancet Oncol. 2017. V. 18. p. 1624-1636.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Gandhi, M. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase III randomized controlled trial / Mihir Gandhi, Su Pin Choo, Choon Hua Thng et al. //. BMC Cancer. 2016. 16:856.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Chow, P. K. H. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma / Pierce K.H. Chow, Mihir Gandhi, Say-Beng Tan //. J Clin Oncol. 2018; Jul. V. 36 (19). p. 1913-1921.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. Gibbs, H. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study / Peter Gibbs, Val Gebski, Mark Van Buskirk et al. //. BMC. Cancer. 2014. V. 14. p. 897.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. van Hazel, G. A. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer / G. A. van Hazel, V. Heinemann, N. K. Sharma et al. //. J Clin Oncol. 2016; May. V. 34 (15). p. 1723-1731.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. Wasan, H. S. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials / Harpreet S. Wasan, Peter Gibbs, Navesh K. Sharma et al. //. Lancet Oncol. 2017. V. 18. p. 1159-1171.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Virdee, P. S. Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer / P. S. Virdee, J. Moschandreas, V. Gebski //. JMIR Res Protoc. 2017. V. 6 (3). e 43.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Smits, M. L. J. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial / Maarten L.J. Smits, Johannes F.W. Nijsen, Maurice A.A.J. van den Bosch et al. //. Journal of Experimental &amp; Clinical Cancer Research. 2010. 29:70.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. Smits, M. L. J. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study / Maarten L.J. Smits, Johannes F.W. Nijsen, Maurice A.A.J. van den Bosch et al. //. Lancet Oncol. 2012; Oct. V. 13 (10). p. 1025-1034.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. Braat, A. J. A. T. Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial) / Arthur J. A. T. Braat, Dik J. Kwekkeboom, Boen L. R. Kam et al. //. BMC Gastroenterology. 2018. 18:84.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. van den Hoven, A. F. Surefire infusion system versus standard microcatheter use during holmium-166 radioembolization: study protocol for a randomized controlled trial / Andor F. van den Hoven, Jip F. Prince, Rutger C. G. Bruijnen et al. //. Trials. 2016. 17:520.</mixed-citation></ref></ref-list></back></article>
